FEB 20, 2017 08:00 AM PST

Getting started with siRNA: considerations and recommendations

Speakers
  • Senior Product Manager, GE Healthcare
    Biography
      The speaker is Louise Baskin, MS, senior product manager, GE Healthcare. Louise, who joined Dharmacon RNA Technologies in 2005, has led the development and commercial launch of multiple genome-wide siRNA and microRNA product lines. She is also responsible for developing and expanding the Dharmacon Edit-R Genome Engineering portfolio, which includes synthetic crRNA and lentiviral sgRNA, in addition to Cas9 nucleases in inducible or constitutive lentiviral vectors, DNA plasmid, mRNA, or protein formats. She works closely with a respected team of R&D scientists on innovative CRISPR-Cas9 tools and services. Louise earned a master's degree in molecular biology and genetics at Northwestern University.

    Abstract:

    This is an introduction to the biological mechanism of RNA interference (RNAi) and experimental application of short, interfering RNA (siRNA). The key steps of the endogenous RNAi pathway will be explained to provide context for the mechanism of targeted gene knockdown with siRNA. The critical factors that affect siRNA function and specificity (off-targeting), such as siRNA design, chemical modifications and concentration, will be covered in detail. The practical application of siRNA will be covered through discussion of best-practice for experimental design. This will include proper use of positive and negative controls, optimization of transfection, and siRNA concentration. Measurement of gene knockdown and appropriate interpretation of experimental outcomes will round out the discussion. In this webinar, attendees will learn:

    • Key steps of the endogenous RNAi pathway
    • siRNA mechanism of action
    • Best practices for siRNA experimental design
    • Appropriate interpretation of experimental outcomes


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    NOV 14, 2017 09:00 AM PST
    C.E. CREDITS
    NOV 14, 2017 09:00 AM PST
    DATE: November 14, 2017TIME: 09:00am PST, 12:00pm ESTThe CRISPR-Cas9 system has been adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and av...
    OCT 19, 2017 08:00 AM PDT
    C.E. CREDITS
    OCT 19, 2017 08:00 AM PDT
    DATE: October 19, 2017TIME: 08:00am PDT, 11:00am EDT Recent FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    Loading Comments...